Meditech begins second stage of Phase II
Monday, 06 December, 2004
Meditech Research (ASX:MTR) has commenced the second stage of its Phase II trial of HyCAMP, its proprietary formulation of chemotherapeutic drug irinotecan in combination with hyaluronic acid.
The trial will examine the safety and efficacy of HyCAMP and compare it to irinotecan alone in 86 patients previously treated with 5-fluorouracil. The trial is expected to be completed in mid-2006.
In an earlier uncontrolled study testing HyCAMP in twelve patients, the treatment showed similar efficacy with improved safety.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
